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Interstitial lung diseases are common and have varied etiology, clinical presentation, 
clinical course and outcome. They pose a diagnostic challenge to physicians and 
pulmonologists. Patients present with dry cough, exertional dyspnoea, interstitial 
lesions on X-ray of the chest and restrictive ventilatory defect on spirometry. A sharp 
decline in oxygen saturation with exercise is characteristic. Careful evaluation of the 
history of the patient and physical examination help in narrowing down diagnostic 
probabilities. HRCT of the chest has emerged as an important tool in the evaluation of 
these disorders. Idiopathic Interstitial Pneumonias (IIP) are a group of conditions 
which are classified into several types based on pathological features. Bronchoscopic 
procedures are helpful in diagnosis of certain disorders but are of limited value in 
classification of IIP which requires surgical biopsy. Usual Interstitial Pneumonia 
(UIP), also referred to as Idiopathic Pulmonary Fibrosis, has a progressive course and 
an unfavourable outcome. Certain new drugs have recently become available for 
treatment of UIP. Our approach towards diagnosis and management of interstitial lung 
diseases based on personal experience over the past three decades is reported here. 
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INTRODUCTION
Interstitial lung diseases (ILD) 
have numerous causes, varied clinical 
presentation and non-specific radiological 
findings which make definitive diagnosis 
a challenging task. Idiopathic interstitial 
pneumonia (IIP) constitute a bulk of ILDs 
referred to pulmonologists for diagnosis 
and management. Idiopathic Pulmonary 
Fibrosis (IPF), also referred to as Usual 
Interstitial Pneumonia (UIP) is the most 
common form of IIP and is associated with 
a poor prognosis. Lung biopsy is often 
recommended for definitive diagnosis of 
ILDs and IIPs. Even experienced lung 
pathologists are sometimes unable to 
make a definitive diagnosis, particularly 
on tiny trans-bronchial lung biopsy 
(TBLB) specimens. Adequate lung biopsy 
specimen requires an open surgical biopsy 
which is often a formidable task in these 
patients who may have severely 
compromised pulmonary reserve even at 
the time of first presentation. A 
coordinated approach with chest 
physician, radiologist, microbiologist and 
pathologist is required for best results. 
Therapeutic trial with treatment directed 
at the most likely diagnosis is sometimes 
justified.
Clinical Features:
The spectrum of disorders which 
may present with features of ILD is very 
large. Careful clinical, radiological, 
functional and laboratory evaluation is 
often helpful in narrowing down the 
diagnostic probabilities. ILD presents 
with a clinical triad of dry cough with 
exertional dysnpoea, reticulo-nodular 
opacities on X-ray of the chest, and 
restrictive ventilatory and diffusion 
defects with sharp fall in oxygen 
saturation on exercise. Presentation may 
be acute, sub-acute or insidious (Table 1). 
Table 1 : Common ILDs according to onset of clinical presentation
Acute
 
Sub-acute
 
Insidious
 

 
Infections (TB, viral, fungus, 
mycoplasma, PCP)
 

 
Hypersensitivity 
pneumonitis
 
 

 
Pneumoconiosis
 
 

 
Intrapulmonary haemorrhage 
(Goodpastures, SLE, WG, 
Idiopathic pulmonary 
hemosiderosis, bleeding 
diathesis) 

 
Tropical pulmonary 
eosinophilia
 
 

 
Idiopathic interstitial 
pneumonias 
 
 
 Pulmonary congestion, LVF  Infections: TB, fungus    Collagen vascular 
disease (PSS, RA, 
overlap syndrome)  
 Acute injury related to drugs, 
fumes, radiation 
 Sarcoidosis    Chronic eosinophilic 
pneumonia   
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Detailed clinical history is of 
utmost importance and cannot be 
superceded by expensive and invasive 
investigations. Of particular note are 
a t t e n t i o n  t o  o c c u p a t i o n a l  a n d  
environmental exposures, drug intake, 
constitutional symptoms, extra-thoracic 
manifestations, associated co-morbidities 
(diabetes mellitus, heart failure, HIV 
infection, malignancy) and rate of 
progression of disease. 
Tables 2 and 3 list important clinical 
features which are helpful in differential 
diagnosis of ILDs.
 Acute idiopathic interstitial 
pneumonia 
 Drug, radiation induced, 
oxygen toxicity
 
  Sarcoidosis  
 
  
Cryptogenic 
organizing pneumonia
 

 
Langerhans cell
histiocytosis
 
 
 
 

 
Non-specific interstitial 
pneumonitis
 
 
 

 
Collagen vascular 
disease
 
 
 
 

 
Carcinomatosis 
lymphangitis  
 Age: Sarcoidosis, RA, SLE, PSS, Sjogren's syndrome common in young, IIPs 
(particularly UIP) in the older age groups
 Gender: CVDs, Lofgren's syndrome in women
 Tobacco smoking: DIP, respiratory bronchiolitis associated IIP
 Occupational exposure: Hypersensitivity pneumonitis, pneumoconiosis
 Onset of symptoms: Acute, subacute or chronic
 Drug intake: cytotoxics, amiodarone, NFT
 Family history: sarcoidosis, UIP
 Febrile illness: infections, SLE, vasculitis, sarcoidosis, TPE
 Hemoptysis: vasculitis (WG), pulmonary haemorrhage, hemosiderosis, 
Goodpasture's
 Athralgia/arthritis: sarcoidosis (ankle arthritis), RA (hands)
 Skin lesions: Sarcoid lesions, EN, vasculitic ulcer, subungual infarct, heliotrope, PSS, 
rheumatoid nodule, butterfly rash
 Eye involvement: Uveitis, conjunctivitis, scleritis, xerophthalmia in sarcoidosis, 
CVD, WG, Sjogren's
 Peripheral lymphadenopathy: TB, sarcoid, fungal infection, HIV
 Digital clubbing: UIP
 Raynaud's phenomenon: PSS
Table 2 :  Clinical characteristics helpful in differential diagnosis
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Sarcoidosis : 
 It is an important cause of 
interstitial lung disease when it progresses 
to stage II or beyond. Sometimes stage I 
disease, characterized by large bihilar and 
right paratracheal lymphadenopathy, 
remains unrecognized because of paucity 
of symptoms at that stage and patients 
present after the development of 
respiratory symptoms and interstitial 
pulmonary infiltrates. A routine enquiry 
regarding the availability of any old x-rays 
of the chest is sometimes rewarding as it 
may show characteristic radiological 
abnormalities which had been missed 
earlier.
 Sarcoidosis is a multi-system 
disorder (1) with involvement of cervical 
lymph nodes, salivary and lacrimal 
glands, eyes, brain, heart, skin, joints, 
erythema nodosum, Bell 's palsy, 
hypercalcemia, hepatosplenomegaly, and 
constitutional symptoms such as fever in 
some of the patients. There are widespread 
non-caseating granulomas in one or more 
of these organs whose biopsy would help 
in confirming the diagnosis. Intrathoracic 
disease is present in almost all at various 
stages of disease. Tuberculin skin test is 
negative and serum angiotensin 
converting enzyme is raised in a majority 
of patients with active disease. We have 
reported observations on various aspects 
of sarcoidosis several years ago when this 
disease was considered relatively 
uncommon in India (2-6).
 In stage II and III disease, the 
magnitude of pulmonary parenchymal 
involvement on X-ray of the chest is out of 
proportion to the clinical symptoms, 
particularly shortness of breath, 
adventitious sounds in the chest, 
pulmonary dysfunction, and lung 
shrinkage. Extensive pulmonary fibrosis 
with marked disability and severe 
hypoxemia is a late development after 
several years or decades of disease.
 At the stage of mediastinal 
lymphadenopathy and mild pulmonary 
infiltration (Stage I or early stage II 
disease), the differential diagnosis is 
main ly  tuberculos is .  F iberopt ic  
Table 3 : Clinical features helpful in differential diagnosis
 Dyspnea aggravated by exercise, rapid shallow breathing, labored respiration, fall 
in SpO2 with exercise are characteristic of most forms of ILDs
 Bibasilar fine inspiratory crepitations (velcro) and digital clubbing are 
characteristic of UIP. 
 Few symptoms (dyspnea and cough) and crepitations despite significant 
radiological abnormalities favor sarcoidosis
 Few crepitations despite dyspnea and radiological findings seen in PSS, 
pneumoconiosis 
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procedures including transbronchial 
needle aspiration from the lymph node are 
often undertaken, but they are unhelpful in 
differentiating between the two conditions 
as AFB stains and culture are rarely 
positive. 
 Progression to stage III is 
a s s o c i a t e d  w i t h  r e g r e s s i o n  o f  
characteristic hilar and mediastinal 
lymphadenopathy and increase in 
pulmonary parenchymal lesions. On 
HRCT of the chest the lung lesions are 
characterized by pulmonary reticulo-
n o d u l a r  l e s i o n s  w i t h  p e r i -
bronchovascular configuration which is 
distinct from sub-pleural interstitial septal 
thickening seen in UIP or NSIP.
 Oral steroids are the mainstay of 
treatment for patients with stage II or III 
disease. Treatment should be initiated 
only when the patient is sufficiently 
symptomatic, as there is no evidence to 
suggest that the long term outcome is 
influenced by early treatment. Patients 
requiring prolonged steroid or other 
immunosuppressant therapy should be 
carefully assessed for the need of 
prophylactic anti-tuberculosis drugs to 
prevent reactivation of latent tuberculosis, 
particularly when the probability of 
tuberculosis can not be ruled out.   
 Overal l ,  the  d iagnosis  of  
sarcoidosis is much simpler, and the 
prognosis much better, compared to IIPs: 
UIP or NSIP.
Hypersensitivity Pneumonitis : 
 Numerous environmental and 
occupational exposures may lead to 
hypersensitivity pneumonitis (7). High 
level of clinical suspicion, detailed history 
of environmental exposures, predominant 
involvement of upper and mid-zones, 
demonstration of precipitins against 
common offending antigens, mild 
peripheral blood eosinophilia and 
favourable response to oral steroids 
characterize this disorder. Farmer's lung 
and exposure to pigeons are the most 
frequent disorders in India, but remain 
largely undiagnosed because of the lack of 
facilities for serological diagnosis.     
Pneumoconiosis : 
 Several forms of pneumoconiosis 
are associated with interstitial lung 
disease with variable degree of fibrosis. 
Incidence of silicosis has gone down in the 
recent years with greater awareness of this 
dreadful disease and stricter enforcement 
of industrial hygiene at work place in the 
organized sector. Occasional patients with 
silicosis are still encountered amongst 
those exposed to dust in stone-crushing 
industry. Diagnosis is straightforward 
once the occupational history is obtained, 
but the disease has also been noted in 
those living or working in the vicinity of 
the stone crushers. Relentless progression 
of disability and destructive and 
sometimes conglomerate fibrosis with 
few auscultatory findings on examination 
of the chest are characteristic of this 
disorder. Presence of lymphocytosis in the 
boncho-alveolar lavage fluid, and a 
favourable response to oral steroid 
6 JN Pande
therapy were reported by us many years 
ago (8,9). Silicosis however is a fatal 
disease and almost all patients seen by us 
died within a decade. 
 Asbestosis and coal-workers' 
pneumoconiosis are other forms of 
pneumoconoses seen in India. Their 
incidence is declining rapidly with strict 
enforcement of health safety measures in 
the mining industry. 
Interstitial lung disease secondary to 
collagen vascular diseases : 
 Progressive systemic sclerosis is 
invariably associated with interstitial 
pulmonary fibrosis of variable degree. 
Disease is slowly progressive with 
respiratory failure and pulmonary 
hypertension as the cause of death in most 
patients. Diagnosis is literally written on 
the face, but some patients may have only 
Raynaud's phenomenon and minimal skin 
changes at the time of presentation with 
pulmonary symptoms. Basal inspiratory 
crackles are usually present at the time of 
presentation. We reported beneficial 
effect of oral steroids many years ago, and 
pulse therapy with steroids and 
cyclophosphamide has also been 
practiced. Recent observations, however, 
negate the benefit from these forms of 
treatment and the condition continues to 
progress despite currently available 
therapies.
 Rheumatoid arthritis is the most 
common rheumatological disorder which 
is occasionally associated with pulmonary 
manifestations. Interstitial pulmonary 
fibrosis is one form of lung involvement, 
besides rheumatoid nodules and pleural 
effusion. The diagnosis is relatively 
simple but the joint symptoms in 
sarcoidosis may be confused with 
rheumatoid arthritis in early stages.
 Multi-system involvement with 
distinctive extra-pulmonary features in 
systemic lupus erythematosus,  
d e r m a t o m y o s i t i s ,  We g e n e r ' s  
granulomatosis (10), Churg-Strauss 
Syndrome and systemic vasculitides 
can usually be recognized on the basis of 
clinical features and appropriate 
serological tests.
Infections with an ILD Radiological 
appearance :
 Several infections caused by 
bacteria, fungi and parasites look like ILD 
on an X-ray of the chest. This is an 
important consideration in India where 
infectious diseases continue to be rampant 
a n d  a r e  i m p o r t a n t  d i a g n o s t i c  
considerations globally. The list of agents 
responsible for ILD like appearance 
radiologically is very large. Most of these 
conditions are acute or sub-acute and 
illness is febrile. Examples include 
interstitial pneumonia caused by atypical 
pathogens and viruses, Pneumocystis, 
m y c o b a c t e r i a  ( 11 )  a n d  f u n g i .  
Bronchoscopic procedures are helpful in 
establishing the microbiological  
diagnosis in some of these patients 
whereas serological investigations are 
helpful in others.
 Tropical pulmonary eosinophilia 
is common in certain parts of the country 
and the diagnosis is established by 
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presence of intense eosinophilia and 
response to diethyl carbamazine.     
 A miscellaneous group of 
conditions may produce a picture of ILD. 
Various conditions include lymphatic 
o b s t r u c t i o n  i n  c a r c i n o m a t o s i s  
lymphangitis, radiation fibrosis, drug 
induced pneumopathies, Langerhans 
histiocytosis, oxygen toxicity, sequel of 
acute respiratory distress syndrome,  
i n t r a - p u l m o n a r y  h a e m o r r h a g e  
(Goodpasture's syndrome, other causes), 
pulmonary hemosiderosis (idiopathic or 
secondary to chronic pulmonary 
congestion in mitral stenosis) and 
pulmonary alveolar microlithiasis. 
Pulmonary congestion due to left 
ventricular dysfunction has sometimes 
been mistaken for ILD; ground-glass 
appearance on HRCT has sometimes 
added to this confusion. Each one of these 
disorders has its own clinical spectrum 
and familiarity with all of them is 
necessary to arrive at a definitive 
diagnosis.
Idiopathic Interstitial Pneumonias 
(IIPs) :
 Exclusion of all of the above 
groups of conditions by appropriate 
clinical history, physical examination, 
radiological and laboratory investigations 
including organ biopsies leaves behind a 
group of conditions included under the 
broad heading of IIPs. These include 
Usual Interstitial Pneumonia also known 
as Idiopathic Pulmonary fibrosis, 
Nonspecific Interstitial Pneumonia 
(NSIP), Acute Interstitial Pneumonia 
( formerly termed Hamman-Rich 
syndrome), Lymphoid Interstitial 
Pneumonia (LIP),  Desquamative 
I n t e r s t i t i a l  P n e u m o n i a  ( D I P ) ,  
Cryptogenic Interstitial Pneumonia 
(COP) or Respiratory Bronchiolitis 
associated pneumonia. UIP and NSIP 
account for majority of patients, other 
conditions are rare. Excellent reviews, 
consensus statements and management 
guidelines have been published in the past 
5 years (12-25). Areas of uncertainty have 
been identified as also the areas for future 
research. We reported our observations on 
idiopathic pulmonary fibrosis in India 
several years ago (26,27). Considered an 
u n c o m m o n  d i s o r d e r  a n d  o f t e n  
misdiagnosed 25 years ago, IPF today 
accounts for almost 20% of the outpatients 
seen by me at a private hospital. This of 
course may reflect a large referral bias. 
 UIP which accounts for more than 
half of IIPs continues to have a dismal 
prognosis with a median life expectancy 
of 3-5 years. NSIP continues to be poorly 
defined and has a better prognosis with 
favourable response to oral steroids.      
  Radiological features on plain 
X-ray of the chest are shown in Table 4. 
X-ray of the chest is the usual initial 
investigation which raises the suspicion of 
interstitial lung disease. It also shows the 
type, extent, severity and distribution of 
the lung lesions. Presence of lung 
shrinkage, if present, can also be noted. 
The type of lung lesions, their distribution, 
presence of associated mediastinal 
lymphadenopathy, pleural involvement, 
honeycombing, ground glass appearance, 
cardiomegaly, pulmonary venous 
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hypertension, and several other features 
provide important clues regarding the 
likely diagnosis.
 HRCT of thorax has emerged as 
one of the most important investigations 
in the evaluation of patients with ILD. 
Careful evaluation of distribution 
interstitial septal thickening noting its 
dis t r ibut ion (patchy or  diffuse,  
symmetrical or asymmetrical, basal or 
upper zone predominance, subpleural or 
interlobar, interlobular or peribroncho-
vascular predominance), presence 
honeycombing, traction bronchiectasis, 
a i r - t r a p p i n g ,  a n d  g r o u n d - g l a s s  
a p p e a r a n c e ,  m e d i a s t i n a l  
l y m p h a d e n o p a t h y,  a n d  p l e u r a l  
involvement are extremely helpful in 
different ia t ing usual  in ters t i t ia l  
pneumonia (UIP or idiopathic pulmonary 
fibrosis) from non-specific interstitial 
pneumonia (NSIP), desquamative 
interstitial pneumonia (DIP), cryptogenic 
organizing pneumonia, hypersensitivity 
pneumonitis, and sarcoidosis. A typical 
UIP pattern on HRCT with typical 
bibasilar velcro crepitations and digital 
clubbing virtually confirms the diagnosis 
of UIP and obviates the need of open 
surgical biopsy of the lung. CT chest is 
diagnostic in Langerhans histiocytosis 
and miliary tuberculosis. Presence of 
necrotic and conglomerate mediastinal 
lymphadenopa thy  i s  he lpfu l  in  
differentiating tuberculosis from 
sarcoidosis.
 Bronchoscopic procedures are 
useful in some patients when sarcoidosis, 
intra-pulmonary haemorrhage, DIP or 
infectious disorders (e.g., tuberculosis, 
fungal infections, Pneumocystis etc) are 
being considered. Bronchoscopic 
procedures include bronchial biopsy, 
transbronchial lung biopsy, trans-
tracheal/bronchial needle aspiration and 
bronchoalveolar lavage fluid analysis. We 
have reported our observations of 
broncho-alveolar lavage in a variety of 
patients with interstitial lung diseases 
i n c l u d i n g  s a r c o i d o s i s ,  m i l i a r y  
tuberculosis, silicosis, tropical pulmonary 
eosinophilia and several others (28-30). 
However, undertaking bronchoscopic 
procedures in patients with HRCT 
findings suggestive of UIP or NSIP is non-
c o n t r i b u t o r y  a n d  u n r e w a r d i n g .  
Table 4 :  Radiological findings on plain radiograph of chest
 Reticular, reticulonodular lesions, often more prominent at the bases
 Micronodular lesions, miliary shadows
 Diffuse alveolar damage, ground glass
 Lung shrinkage
 Honeycombing, cystic lesions, cavitations
 Hilar, mediastinal lymphadenopathy
 Pleural reaction, pneumothorax, calcification
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Immunological investigations are helpful 
in the diagnosis of ILD secondary to 
collagen vascular diseases in patients with 
joint and skin involvement. Presence of 
anti-neutrophilic cytoplasmic antibodies 
(ANCA) in patients with lung nodules 
would confirm the diagnosis of Wegener's 
granulomatosis without a lung biopsy. 
Presence of antinuclear antibodies or 
rheumatoid factor in high titers would 
suggest appropriate diagnosis; low titers 
are not uncommon in UIP and NSIP. 
Biopsy/FNAC of easily accessible organs 
such as skin, subcutaneous nodules, 
parotid, and palpable peripheral lymph 
nodes are highly rewarding in patients 
with such lesions. 
 UIP is a dreaded disease which is 
relentlessly progressive and ends fatally 
within 3-4 years after diagnosis. It does 
not respond to steroids except for 
providing temporary relief during acute 
exacerbations. It can mostly be diagnosed 
from clinical features and HRCT findings, 
but an open lung biopsy (transthoracic 
route using VATS) may be required for 
patients with overlapping features. 
American Thoracic Society has proposed 
certain criteria for the diagnosis of UIP 
which may be adequate for diagnosis in 
the absence of lung biopsy (Table 5).
Table 5 : ATS/ERS criteria for diagnosis of idiopathic pulmonary fibrosis 
in absence of surgical lung biopsy 
Major Criteria: 
1. Exclusion of other known causes of ILDs such as certain drug toxicities, 
connective tissue diseases, environmental exposures
2. Abnormal lung functions with restrictive ventilatory defect, impaired gas 
exchange with hypoxemia worsened by exercise and impairment of 
pulmonary diffusing capacity
3. Bibasilar reticular opacities with minimal ground glass changes on HRCT 
4. Transbronchial lung biopsy or BAL showing no features to support an 
alternative diagnosis
Minor Criteria:
1. Age >50 years
2. Insidious onset 
3. Duration of illness more than 3 months
4. Bibasilar Velcro crepitations
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 NSIP appears to be related to some 
kind of poorly defined immunological 
disorder at the present time. It responds to 
oral steroids and has a much better 
prognosis. DIP occurs mainly in elderly 
smokers, responds well to steroids after 
smoking cessation, and has good 
prognosis. COP also is steroid responsive, 
but the final prognosis depends on its 
cause.  Sarcoidosis  is  eminently 
responsive to steroids. Use of steroids in 
patients with tuberculosis or other 
infections may be disastrous. Prolonged 
use  of  s te ro ids ,  wi thout  us ing  
chemoprophylaxis in patients with latent 
tuberculosis (tuberculin or interferon 
gamma release assay positive) may also 
spell trouble. There are no clear guidelines 
on this issue in our country, and clinical 
judgement is required for risk/ benefit 
analysis.
Major clinical features of IIPs  have 
been summarized in Tables 6-12
Table 6 : Idiopathic pulmonary fibrosis (Usual interstitial pneumonia)
 Most common and dreaded form of IIP
 More common in older subjects, males
 Basal predominant reticular lesions, patchy and asymmetrical, lung shrinkage
 Subpleural interstitial septal thickening, honeycombing, bronchiolectasis, 
traction bronchiectasis, architectural distortion, rare focal ground-glass. (UIP 
appearance)
 50-80% mortality in 5 years; more lethal and disabling than many cancers
Table 7 :  Non-specific interstitial pneumonia
 Subacute to chronic; 25% of IIP
 Ground-glass and reticular opacities on X-ray chest. CT shows peripheral 
distribution, sub-pleural location, basal predominance, symmetrical interstitial 
septal thickening, ground-glass appearance, honeycombing unusual
 Cellular and non-cellular NSIP pathology
 Overlap with UIP appearance common
 Responds to corticosteroids; <10% mortality in 5 years
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Table 9 : Acute interstitial pneumonia
 Rare disorder (? Same as Hamman-Rich)
 Characterized by diffuse alveolar damage pathologically
 Progressive diffuse ground-glass density or consolidation on X-ray chest and 
CT
 Differential diagnosis: Pneumonia, pulmonary edema
 Steroids may be tried
 60% mortality in <6 months
Table 8 :  Cryptogenic organizing pneumonia
 10% of IIP
 Patchy bilateral consolidation on X-ray chest
 CT: peripheral/peribronchial distribution of patchy consolidation and/or 
nodules
 Differential diagnosis includes infections, sarcoidosis, vasculitis, 
bronchoalveolar carcinoma, NSIP
 Steroid responsive; death rare
Table 10 :  Desquamative interstitial pneumonia
 Subacute/chronic disorder in smokers, accounting for 15% of IIP 
 Ground-glass attenuation on X-ray chest and CT: lower zone and peripheral 
predominance, reticular lines
 Differential diagnosis: PCP, sarcoidosis, hypersensitivity pneumonitis, RB-
ILD
 Smoking cessation and steroids are curative; 5% mortality in 5 years
Table 11 :  Respiratory bronchiolitis associated interstitial pneumonia
 Subacute/chronic disorder in smokers
 X-ray chest and CT show bronchial wall thickening, centrilobular nodules, 
patchy ground-glass opacities
 Differential Diagnosis: DIP, NSIP, HSP
 Smoking cessation and steroids highly effective, mortality 5% in 5 years
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 Definitive treatment for UIP is 
lung transplantation. This is currently not 
available in our country for lack of brain-
dead organ donors. Not advising this 
option for patients in the US may land 
physicians in legal trouble. Not advising 
open lung biopsy in suspected UIP may 
also spell the same. The experience of 
Indians going to the US for lung 
transplantation has been pathetic.
 Is there any hope for patients with 
UIP beyond symptomatic treatment, 
family and physician support, BiPAP or 
CPAP, continuous oxygen therapy, 
antibiotics when indicated, and occasional 
u s e  o f  s t e r o i d s  d u r i n g  a c u t e  
exacerbations? N-acetyl cysteine was 
reported to retard the progression of 
disease three years ago. The drug has no 
major side-effects and may be used for all 
patients with UIP (31). The use of 
azathioprine, a cytotoxic drug,is no longer 
justifiable in view of the recent reports. 
The use of Pirfenidone (pirfinex) has been 
shown to be beneficial in retarding the 
progression of disease in a meta-analysis 
of four published RCTs. (32,33,34*). It 
appears to be a logical choice in our 
present state of ignorance about this 
disease. It is being extensively used in 
patients with UIP in India. It became 
available in India ahead of its approval by 
the FDA for use in the US. Although there 
are no published reports, both physicians 
and the patients appear satisfied with the 
outcome. The risk of development of skin 
cancers appears less likely in Indians who 
have lower incidence of cancers caused by 
exposure to UV radiations. Acute 
exacerbations of UIP respond to short 
courses of steroids. 
 Palliative care is as important in 
the management of patients with 
advanced pulmonary fibrosis and 
respiratory failure as in cancer 
management. The expected natural 
history of disease along with likely 
complications needs discussion with the 
family members and the patient. End of 
life issues also need to be discussed. 'Non-
abandonment' of the patient who becomes 
terminally ill is important. Advance 
directives from the patient and the family 
members regarding the use of ventilator 
support in the intensive care unit would 
help physicians make informed choices.  
Table 12 :  Lymphoid interstitial pneumonitis
 Rare disorder, females predominate
 Diffuse reticular opacities and nodules on x-ray chest
 CT: centrilobular nodules, ground-glass, septal and bronchovascular 
thickening, thin walled cysts
 Differential diagnosis: Sarcoidosis, lymphangitis carcinomatosis, Langerhans 
cell histiocytosis
 Steroid responsive
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